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Abstract
Abnormal liver biochemical tests are present in up to 
30% of patients with inflammatory bowel disease (IBD), 
and therefore become a diagnostic challenge. Liver 
and biliary tract diseases are common extraintestinal 
manifestations for both Crohn’s disease and ulcerative 
colitis (UC), and typically do not correlate with intesti-
nal activity. Primary sclerosing cholangitis (PSC) is the 
most common hepatobiliary manifestation of IBD, and 
is more prevalent in UC. Approximately 5% of patients 
with UC develop PSC, with the prevalence reaching up 
to 90%. Cholangiocarcinoma and colon cancer risks 
are increased in these patients. Less common disorders 
include autoimmune hepatitis/PSC overlap syndrome, 
IgG4-associated cholangiopathy, primary biliary cir-
rhosis, hepatic amyloidosis, granulomatous hepatitis, 
cholelithiasis, portal vein thrombosis, liver abscess, and 
non-alcoholic fatty liver disease. Hepatitis B reactivation 
during immunosuppressive therapy is a major concern, 
with screening and vaccination being recommended in 
serologically negative cases for patients with IBD. Re-
activation prophylaxis with entecavir or tenofovir for 6 
to 12 mo after the end of immunosuppressive therapy 
is mandatory in patients showing as hepatitis B surface 
antigen (HBsAg) positive, independently from viral load. 
HBsAg negative and anti-HBc positive patients, with or 
without anti-HBs, should be closely monitored, measur-
ing alanine aminotransferase and hepatitis B virus DNA 
within 12 mo after the end of therapy, and should be 
treated if the viral load increases. On the other hand, 
immunosuppressive therapy does not seem to promote 
reactivation of hepatitis C, and hepatitis C antiviral 
treatment does not influence IBD natural history either. 
Most of the drugs used for IBD treatment may induce 
hepatotoxicity, although the incidence of serious ad-
verse events is low. Abnormalities in liver biochemical 
tests associated with aminosalicylates are uncommon 
and are usually not clinically relevant. Methotrexate-
related hepatotoxicity has been described in 14% of 
patients with IBD, in a dose-dependent manner. Liver 
biopsy is not routinely recommended. Biologics-related 
hepatotoxicity is rare, but has been shown most fre-
quently in patients treated with infliximab. Thiopurines 
have been associated with veno-occlusive disease, 
regenerative nodular hyperplasia, and liver peliosis. 
Routine liver biochemical tests are recommended, es-
pecially during the first month of treatment. All these 
conditions should be considered in IBD patients with 
clinical or biochemical features suggestive of hepatobili-
ary involvement. Diagnosis and management of these 
disorders usually involve hepatologists and gastroenter-
ologists due to its complexity.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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testinal manifestations of inflammatory bowel disease 
(IBD) that become a diagnostic challenge for the gas-
troenterologist. In this review, we have summarized 
the main diseases involving the hepatobiliary system in 
IBD and secondary liver toxicity to IBD treatment. This 
review also highlights the impact of immunosuppressive 
and anti-tumor necrosis factor treatment in hepatitis B 
and C, as well as its prophylaxis and treatment, accord-
ing to current clinical practice guidelines. 
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INTRODUCTION
Hepatobiliary diseases are relatively common in inflam-
matory bowel disease (IBD) and therefore become a diag-
nostic challenge. Liver and biliary tract disorders are typi-
cal extraintestinal manifestations in both Crohn’s disease 
(CD) and ulcerative colitis (UC). In patients receiving 
immunosuppressive therapy, including biologics, the risk 
of  hepatitis B reactivation is high, so patients undergoing 
this therapy should be screened for hepatitis B surface 
antigen (HBsAg) and anti-HBc prior to starting the treat-
ment. Most of  the drugs used for IBD treatment have 
also been associated with hepatotoxicity. All these condi-
tions should be ruled out in IBD patients with clinical or 
biochemical features suggestive of  liver involvement, as 
summarized in this review. 
Bibliographic searches were performed in the MED-
LINE electronic database up to February 2013 using the 
Medical Subject Headings terms: (“inflammatory bowel 
disease” OR “Crohn’s disease” OR “ulcerative colitis”) 
AND (“liver” OR “biliary tract” OR “primary sclerosing 
cholangitis” OR “hepatobiliary disorders” OR “small-
duct PSC” OR “PSC/AIH overlap syndrome” OR 
“IgG4-associated cholangitis” OR “primary biliary cir-
rhosis” OR “hepatic amyloidosis” OR “granulomatous 
hepatitis” OR “cholelithiasis” OR “portal vein thrombo-
sis” OR “liver abscess” OR “non-alcoholic fatty liver dis-
ease” OR “viral hepatitis” OR “hepatitis B” OR “hepatitis 
C” OR “drug-induced liver injury” OR “drug-induced 
hepatitis” OR “hepatotoxicity”).
HEPATOBILIARY DISORDERS 
ASSOCIATED WITH INFLAMMATORY 
BOWEL DISEASE
Hepatobiliary manifestations constitute some of  the 
most common extraintestinal manifestations of  IBD. 
They typically adopt an independent course irrespective 
of  intestinal activity and are present in both UC and CD. 
Primary sclerosing cholangitis
Primary sclerosing cholangitis (PSC) is a chronic fibroes-
clerotic disorder of  the intrahepatic and extrahepatic 
biliary tree. and is the most common hepatobiliary mani-
festation of  IBD. The association of  PSC and IBD was 
described for first time in 1965[1]. 
Epidemiology: Approximately 70%-80% of  patients 
with PSC have concomitant IBD and about 1.4%-7.5% 
of  patients with IBD will develop PSC[2]; however the 
course of  IBD is not related to PSC. It is more prevalent 
in males, in UC, and in young and middle-aged patients[3]. 
UC has been reported in 25 to 90 percent of  patients 
with PSC[4]. In a Spanish multicenter study, based on a 
survey, UC was present in 44%[5]. Nevertheless, the real 
prevalence of  UC in PSC is up to 90% when rectal and 
sigmoid biopsies are routinely obtained[6].
PSC is typically characterized by progressive inflam-
mation, obliterative fibrosis, and destruction of  intra- and 
extrahepatic bile ducts, leading to end-stage liver disease 
and portal hypertension[7]. Patients with PSC may also de-
velop complications such as cholestasis-associated mani-
festations, biliary stricture, cholangitis, cholelithiasis, chol-
angiocarcinoma, and colon cancer. The diagnosis of  PSC 
is usually previous to IBD, but PSC may be diagnosed 
over time, after a proctocolectomy in UC patients[8]. 
Etiology: The etiology of  PSC remains unclear. Ge-
netic, immunological, and environmental factors seem 
to contribute to its pathogenesis. First-degree relatives 
of  patients with PSC show an increased risk of  PSC 
and UC, supporting a genetic predisposition to these 
conditions[9]. Multiple genetic factors associated with 
susceptibility have been described, like HLA-B8, HLA-
DRB1*0301 (DR3), HLADRB3*0101 (DRw52a), and 
HLA-DRB1*0401 (DR4)[10,11]. In addition, three UC sus-
ceptibility loci have been associated with PSC, harboring 
the presumed candidate genes REL, IL2, and CARD9[12]. 
An autoimmune mechanism has been suggested, since 
both are immune-mediated disorders, and are also as-
sociated with other autoimmune diseases. Several auto-
antibodies may be present, such as antinuclear antibodies 
(ANA) in 24%-53%, smooth muscle antibodies (SMA) 
in 13%-20%, and anti-perinuclear cytoplasmic antibodies 
(pANCA) in 65%-88% of  patients[13-15]. Other autoan-
tibodies, including anticardiolipin, thyroperoxidase, and 
rheumatoid factor may be present, but show uncertain 
clinical significance. In one study, 97% of  cases with PSC 
were positive for, at least, one autoantibody, while 81% 
were positive for three or more[16]. An inflammatory re-
sponse to chronic or recurrent bacterial infection into the 
portal circulation or ischemic damage to the bile ducts 
has also been postulated[17]. Therefore, the most plausible 
theory involves the exposure of  genetically predisposed 
individuals to an environmental agent that provokes an 
anomalous immune response, leading to disease develop-
ment. 
IBD in PSC patients has a distinct behavior, as it 
shows a higher incidence of  rectal sparing, backwash 
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ileitis, extensive colitis, pouchitis after ileal pouch anal 
anastomosis, colon dysplasia, colon cancer, and poorer 
prognosis[18-21]. Patients with UC and PSC usually have a 
lower grade of  colon inflammation and a milder course, 
compared to patients without PSC[22]. In addition, severe 
progressive PSC requiring liver transplantation appears to 
reduce histological activity and the need for colectomy in 
UC[23,24].
Diagnosis: Most patients with PSC are asymptomatic at 
diagnosis. This disease should be considered in patients 
with IBD and abnormal liver biochemical tests, where a 
marked elevation of  serum alkaline phosphatase is com-
monly found[25]. In symptomatic patients, fatigue and 
pruritus are common. Other features include abdominal 
pain, jaundice, and weight loss. Cholangitis occurs in 
10%-15% of  patients during the course of  the disease. 
Biochemical tests usually show a cholestatic pattern. 
Aminotransferases levels are typically lower than 300 IU/
L. Additional biochemical parameters are hypergamma-
globulinemia (30% of  cases), increased serum IgM levels 
(40%-50%), and p-ANCA (30%-80%). Serum albumin 
levels later decrease during the course of  the disease, and 
the presence of  hypoalbuminemia earlier may indicate ac-
tive IBD.
Diagnosis is established by the demonstration of  dif-
fuse, multifocal strictures and dilations in the intra- and 
extrahepatic bile ducts. In 41% of  cases, the gallbladder 
and cystic duct may also be involved[26]. In the early stages 
of  the disease, superficial ulcerations of  the bile ducts 
may be the only manifestation found. Endoscopic retro-
grade cholangiopancreatography (ERCP) is considered 
the gold standard technique for PSC diagnosis. It can be 
both diagnostic and therapeutic, and also may be useful 
in the early diagnosis of  cholangiocarcinoma. Magnetic 
resonance cholangiography (MRCP) is a non-invasive al-
ternative with high sensitivity and specificity, and without 
the risks related to the technique[27]. Liver biopsy is only 
recommended in cases of  clinical suspicion of  small-duct 
PSC, as it is rarely diagnostic of  PSC[28]. The most spe-
cific histologic finding in PSC is fibrous obliteration of  
small bile ducts, with periductal concentric fibrosis in an 
“onion skin” pattern. Other abnormalities are non-specif-
ic and similar to those in primary biliary cirrhosis. Liver 
biopsy is helpful for staging the disease and determining 
prognosis. Ludwig described 4 stages of  PSC based on 
morphologic features[29]. 
Prognosis: PSC is a progressive disease that, ultimately, 
results in portal hypertension, cirrhosis, and hepatic fail-
ure. The median survival time without liver transplanta-
tion is approximately 12 years. Survival is significantly 
worse in symptomatic patients at the time of  diagnosis[30]. 
Coexisting IBD may also be related to a poorer prog-
nosis, as it has been associated with a younger age at 
diagnosis, the development of  malignant complications, 
dysplasia and/or colon cancer[31,32]. Patients with PSC 
usually develop complications of  end-stage liver disease 
with portal hypertension, such as varices, ascites, and 
hepatic encephalopathy. The Mayo Risk Score based on 
age, serum bilirubin, albumin, aspartate aminotransfer-
ase, and the presence of  variceal bleeding, has been used 
to assess disease progression and prognosis[33]. Other 
complications include steatorrhea and fat-soluble vitamin 
deficiency, secondary to chronic cholestasis, amyloidosis 
secondary to amyloid A protein deposition in tissues due 
to a progressive inflammatory process[34], dominant bili-
ary strictures, cholangiocarcinoma, and colon cancer. The 
risk for cholangiocarcinoma is significantly increased in 
PSC and its development remains unpredictable. The an-
nual incidence has been estimated as 1.5%[35]. Risk factors 
include the presence of  IBD, cirrhosis, variceal bleeding, 
a dominant stricture in the bile duct, and alcohol intake[36]. 
Worsening jaundice, weight loss, and abdominal discom-
fort are suspicion symptoms. Diagnosis may be difficult, 
as imaging techniques and brush cytology show a lack of  
sensitivity for early detection. However, ERCP and cytol-
ogy of  bile duct strictures is highly specific[37]. Prognosis 
is devastating, with a survival rate of  10% two years after 
diagnosis[38] and a recurrence rate in the transplanted 
liver of  about 20%-25%[39]. Patients with PSC have an 
increased risk for gallbladder cancer, pancreatic cancer 
and, in cirrhotic patients, hepatocellular carcinoma. A 
higher risk of  colorectal dysplasia/cancer has also been 
described among UC patients with PSC[21], even after 
liver transplantation[40]. The severity and the duration of  
PSC have not been significantly associated with the risk 
of  colon cancer[41]. In patients with ileal pouch-anal anas-
tomosis, the risk for dysplasia persists after colectomy[42]. 
Therefore, surveillance for colorectal cancer should be 
strongly recommended in PSC patients with UC[43].
Treatment: Treatment of  PSC associated with UC does 
not differ from PSC without IBD. As no pharmacologic 
therapy has proven effective for PSC, treatment goals 
are the control of  symptoms and the management of  
complications. Ursodeoxycholic acid (UDCA) has been 
shown as effective in liver function improvement based 
on biochemical tests but it had no effect on liver histol-
ogy, liver transplant-free survival, requirements for liver 
transplantation, development of  cholangiocarcinoma, or 
incidence of  death[44,45]. In a meta-analysis, UDCA does 
not appear to decrease either the risk of  adenomas or 
colon cancer[46]. Immunosuppressants, chelators, and ste-
roids have been used without any benefit. 
Liver transplantation is the only therapy that can 
change the inevitable outcome. The appropriate moment 
for liver transplantation can be difficult to determine, as 
patients with advanced disease may not show signs of  
liver failure. Survival rates after hepatic transplant at 5 
and 10 years are 85% and 70%, respectively[47]. However, 
in 20%-25% of  cases, PSC recurs in the transplanted 
liver[39].
Endoscopic management of  PSC is indicated in 
cases of  cholangitis, exacerbate jaundice, or suspicion of  
cholangiocarcinoma. Endoscopic dilation of  dominant 
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cell infiltrating the bile duct and other organs is decisive 
in reaching the diagnosis[58,59]. Clinically, patients with IAC 
are older at diagnosis compared to patients with PSC. 
Obstructive jaundice can be the first symptom, whereas 
it is rarely present in PSC[62]. Steroids are the first-choice 
therapy of  IAC, as they result in the resolution of  jaun-
dice, improve liver laboratory parameters, and reduce 
serum IgG4 levels and the reversal of  strictures on chol-
angiogram[63]. Azathioprine (AZA) should be considered 
alongside those with proximal and intrahepatic stenosis, 
and those that relapse during and ⁄ or after corticosteroid 
therapy[64].
Primary biliary cirrhosis
Primary biliary cirrhosis (PBC) frequently accompanies 
various autoimmune diseases including Sjögren syn-
drome, chronic thyroiditis, and rheumatoid arthritis, but 
rarely IBD[65]. There are a few reported cases of  both dis-
eases in the literature[66,67]. The clinical presentation varies 
from typical PBC; affecting males more frequently, being 
diagnosed at younger age and at earlier stages of  PBC, 
and usually associated with previously diagnosed mild 
left-side UC. Although the pathogenesis of  this disease 
has not yet been clarified, environmental and genetic fac-
tors are considered important in the susceptibility to both 
diseases.
Hepatic amyloidosis
Secondary amyloidosis is an unusual complication of  
IBD, more frequent in CD than in UC (0.9% vs 0.07%)[68]. 
Chronic activity in the bowel contributes to amyloid de-
position in the vasculatures and sinusoids of  almost any 
organ, including the liver. It may present as asymptomatic 
hepatomegaly and is more common in men with colonic 
diseases. Treatment is based on controlling gut inflam-
mation, thereby decreasing the release of  the acute phase 
reactant serum amyloid A[69]. In some cases, colchicine 
can be effective.
Granulomatous hepatitis
Granulomatous hepatitis is another rare complication of  
CD, which is characterized by granulomas on the liver bi-
opsy. The main manifestation is an increase in cholestatic 
enzymes such as alkaline phosphatase. Granulomatous 
hepatitis is often secondary to different medications, 
including sulfasalazine[70]. Other causes are malignancies, 
infections, or CD metastasis[71]. Corticosteroids and im-
munosuppressive drugs have been used in its treatment.
Cholelithiasis
It has been estimated that patients with CD have a doubled 
risk for gallstones comparing to IBD-free controls, while 
UC is not associated with an increased risk[72]. The inci-
dence of  gallstones is raised in patients with Crohn’s ileitis 
or ileal resection, ranging from 13% to 34%[73]. Risk 
factors associated with its development are CD loca-
tion at diagnosis, surgery, and extent of  ileal resection. 
Other factors include the age of  the patient, frequency 
strictures, with or without stenting, has been shown to al-
leviate cholestasis and to improve laboratory test results, 
although it does not prevent disease progression[48].
Small-duct PSC
Small-duct PSC is characterized by laboratory and histo-
logical findings similar to PSC but with normal cholan-
giogram. The presence of  coexisting IBD is required for 
the diagnosis of  this entity[49]. In a large multicenter study, 
80% of  patients with small-duct PSC had concurrent 
IBD (78% UC and 21% CD)[50]. Progression of  small-
duct PSC to PSC was observed in 12%-23% of  cases. 
Small-duct PSC has been associated with a better long-
term prognosis as compared with large-duct PSC. Chol-
angiocarcinoma has not been previously described. Some 
patients may require liver transplantation for end-stage 
liver disease, and the disease may recur after liver trans-
plantation. In IBD patients with cholestatic liver function 
tests altered and a normal cholangiogram by ERCP/
MRCP, a biopsy is recommended to rule out small-duct 
PSC, after excluding other hepatobiliary disorders.
AIH/PSC overlap syndrome: AIH/PSC overlap syn-
drome has been described in patients with IBD, espe-
cially UC[51]. The diagnosis is suspected when features of  
AIH and PSC are present in the same patient, requiring 
a definitive diagnosis of  AIH based on the International 
Autoimmune Hepatitis Group Criteria, which includes 
demographic, histologic, and laboratory markers[52]. 
Diagnosis, treatment, and prognosis of  the overlap syn-
drome are controversial and so standardized diagnostic 
criteria are needed[53,54]. Previous studies have reported 
cases that initially presented with laboratory markers and 
histologic features of  either AIH or both diseases with 
a normal cholangiography, only to develop pathologic 
characteristics of  PSC during the follow-up[52,55,56]. In-
trahepatic and extrahepatic bile ducts may be affected. 
Conventional corticosteroid therapy, alone or in conjunc-
tion with UDCA (13-15 mg/kg daily), has been variably 
effective, and cyclosporine, mycophenolate mofetil, and 
budesonide have been beneficial in selected patients. The 
cholestatic features that influence the prognosis of  auto-
immune hepatitis must be defined and incorporated into 
the definition of  the syndrome[57].
IgG4-associated cholangiopathy
IgG4-associated cholangiopathy (IAC) is a biliary disease 
of  unknown immunopathogenesis. Indistinguishable 
from PSC according to cholangiographic characteris-
tics, it shows distinct histological findings. It is one of  
a variety of  IgG4-related systemic disease and has been 
described in patients with concurrent UC[58]. Clinical di-
agnostic criteria for IgG4-related disease require systemic 
organ involvement, elevated serum IgG4 levels (≥ 135 
mg/dL), and histopathological findings[59]. IgG4 levels 
have also been reported in 9%-36% of  patients with 
PSC, although these levels are usually lower than in pa-
tients with IAC[60,61]. The identification of  IgG4 plasma 
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of  clinical recurrences, length of  hospital stay, and the 
use of  total parenteral nutrition. The pathophysiology of  
cholelithiasis in CD is not well defined. Abnormal mal-
absorption of  bile acids that interfere with enterohepatic 
circulation has been proposed. Moreover, reduced gall-
bladder motility has been described in CD and increased 
gallstone cholesterol concentrations have been identified 
in patients with ileoanal anastomosis[74].
Portal vein thrombosis
IBD is associated with an increased risk of  vascular 
complications, such as arterial and venous thromboem-
bolisms, which are considered extraintestinal manifesta-
tions. Portal vein thrombosis is a rare but potentially 
life-threatening complication, with an incidence in IBD 
patients higher than that of  the general population. In 
a Mayo Clinic study, portal/mesenteric vein thrombosis 
was reported in 1.3% of  IBD cases, with a mortality 
of  50%[75]. Recent abdominal surgery, younger age, and 
female gender are associated with a higher incidence of  
portal vein thrombosis[76]. The factors involved in this 
pathogenesis are diverse. Acquired prothrombotic fac-
tors can be identified, such as inflammation, immobiliza-
tion, extent of  colon disease, surgery, central catheters, 
corticosteroids, and smoking[77,78]. Furthermore, patients 
with IBD have increased platelet counts, factor Ⅴ and Ⅷ 
levels, and fibrinogen, along with decreased antithrombin 
Ⅲ levels. Anticoagulants, such as low-molecular-weight 
heparin and warfarin, are mainstays of  therapy, even in 
the setting of  gastrointestinal bleeding[73]. In the presence 
of  a congenital hypercoagulable state, lifelong systemic 
anticoagulation should be considered, although in other 
prothrombotic conditions, a six-month course provides 
adequate coverage[79].
Liver abscess
The association between liver abscesses and IBD is 
uncommon[80,81], but hepatic abscesses can be an initial 
manifestation of  CD[82]. The mechanism of  abscess de-
velopment may be related to direct extension of  intra-
abdominal abscesses or due to portal pyemia, secondary 
to an increase in intestinal mucosa permeability. Among 
associated risk factors, intra-abdominal abscesses, fistuliz-
ing disease, malnutrition, and treatment with steroids and 
metronidazole have been reported.
Non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD) is a clinic-
pathological syndrome with a histologic spectrum rang-
ing from benign steatosis to non-alcoholic steatohepatitis 
(NASH)[83]. Steatosis is described in up to 50% of  abnor-
mal liver biopsies in IBD patients and has been related 
to colitis severity. It was presumed secondary to severe 
illness, with malnutrition, hypoproteinemia, and corti-
costeroids primarily responsible[84]. On the other hand, 
NAFLD occurs in 8.2% of  the IBD population, which 
is much lower than the frequency reported in the United 
States general population (33.6%). Those patients who 
developed NAFLD tended to be older, and developing 
IBD at an older age normally requires small bowel sur-
gery[85]. It has been reported that IBD patients develop 
NAFLD with fewer metabolic risk factors than non-IBD 
NAFLD patients. In multivariate analysis, hypertension 
(OR = 3.5), obesity (OR = 2.1), small bowel surgeries (OR 
= 3.7), and use of  steroids at the time of  imaging (OR = 
3.7) were independent factors associated with NAFLD. 
NAFLD is also less common among patients who re-
ceived antibodies against tumor necrosis factor alpha 
(anti-TNF-α) therapy. 
VIRAL HEPATITIS AND IBD
Chronic hepatitis B and C are two common diseases. The 
WHO estimates that 350 million people in the world suf-
fer from chronic hepatitis B, and more than 200 million 
from hepatitis C[86,87]. Hepatitis B infection is transmitted 
during delivery or early childhood. Hepatitis C is a blood-
borne disease spread mainly via blood product transfu-
sion and misuse of  illegal drugs. Around 20% of  patients 
with chronic hepatitis B show cirrhosis progression and 
5% are at risk of  developing hepatocellular carcinoma. 
Chronic hepatitis B infection is a dynamic process, 
owing to the interaction between the hepatitis B virus and 
the host immune system. Its natural history is covered 
by five different phases[88] (Table 1): (1) Immunotoler-
ant phase: characterized by positive hepatitis B e antigen 
(HBeAg), higher HBVDNA titre, and normal or near 
normal ALT levels. Liver biopsy at this phase shows mild 
or no inflammatory lesions and scarce non-progressive 
fibrosis; (2) Immunoclearance phase: positive HBeAg, 
lower HBVDNA, and raised aminotransferase levels. Liv-
er histology shows necroinflammatory activity together 
with fibrosis progression. Spontaneous HBeAg clearance 
and anti-HBe seroconversion could occur at this phase; 
(3) HBsAg inactive carrier: characterized by negative 
HBeAg, positive anti-HBe, residual viremia (HBVDNA 
lower than 2000 IU/mL), and ALT levels under the nor-
mal limit. Liver histology shows minimal or no lesions; (4) 
Chronic hepatitis B: HBeAg negative could appear after 
unsuccessful seroconversion. HBVDNA remains quanti-
fiable and ALT levels are fluctuant. Fibrosis progression 
is common; and (5) Resolved infection: characterized by 
loss of  HBsAg and could be a stable phase, with negative 
HBsAg and non-detectable HBVDNA with normal ALT 
levels and excellent prognosis. 
Chronic hepatitis C is a progressive liver disease that 
could evolve to cirrhosis. Risk factors associated with 
fibrosis progression are alcohol consumption, HIV co-
infection, and adult age at infection. 
Chronic hepatitis B patients showing HBVDNA > 
2000 IU/mL and at least moderate necroinflammatory 
activity or fibrosis in a liver biopsy should be treated with 
entecavir or tenofovir and, in selected cases, with pegin-
terferon α-2a. In patients with chronic hepatitis C and 
positive HCVRNA, antiviral treatment should be started. 
In genotype 1, protease inhibitor-based triple therapy is 
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the first choice and, in non-1 genotype, standard pegin-
terferon plus ribavirin. 
Viral reactivation during immunosuppressive therapy 
is a major concern in viral hepatitis B and C. Viral reac-
tivation is defined by an increase of  1 log in viral load or 
re-appearance of  the virus after previous clearance. A 
flare of  ALT is common and in some cases may develop 
into acute liver failure. 
Hepatitis B reactivation depends on two main fac-
tors: (1) type of  immunosuppressive drug used, and (2) 
hepatitis B phase prior to treatment. In a recent meta-
analysis including 14 studies and 485 HBsAg-positive 
patients undergoing chemotherapy, one in three patients 
developed hepatitis and the mortality rate reached 7%. 
Positive HBeAg and detectable HBVDNA, together with 
steroids or rituximab in hematologic neoplasms, were in-
dependent factors associated with the risk of  developing 
reactivation[89]. In patients with HBsAg loss, reactivation 
risk was around 3%-10% and mainly associated with the 
combination of  steroids and rituximab in hematologic 
neoplasms[90].
Hepatitis B reactivation prophylaxis is recommended 
from one week before chemotherapy to 12 mo after ces-
sation of  this therapy. Lamivudine has shown to decrease 
mortality rate[89]. However, it has been associated with an 
increased risk of  developing resistant variants, so drugs 
with a higher genetic barrier, like entecavir or tenofovir[91], 
are recommended if  immunosuppressors need to be used 
for more than one year.
Hepatitis C reactivation management is controversial, 
due to both its frequency and clinical manifestations re-
maining unclear. Hepatitis has been reported in 11% of  
cases and reactivation in 36% of  the few patients with 
HCVRNA evaluated before and after chemotherapy, 
mainly in those treated with rituximab for hematologic 
neoplasms[92]. Interferon-based therapy is not recom-
mended for hepatitis C reactivation prophylaxis. Further 
combination of  direct antiviral drugs could be useful in 
avoiding hepatitis C reactivation in this setting. 
As immunosuppressive drugs, like AZA, methotrex-
ate (MTX), and anti-tumor necrosis factor α (TNFα), are 
being used more frequently in IBD, concerns about viral 
reactivation are increasing.
Hepatitis B and IBD 
At the beginning of  this century, hepatitis B infection 
prevalence was slightly higher in patients with IBD than 
in the general population, which was mainly related to 
increased surgical procedures and blood transfusions[93,94]. 
However, recent studies in France and Spain did not 
confirm these data. Prevalence of  hepatitis B in IBD has 
been estimated to be similar to the general population 
as a consequence of  several health system measures, like 
overall vaccination, safe transfusions, and surgical proce-
dures. Prevalence of  anti-HBc was 7.1% in CD and 8% 
in UC in a Spanish population[95,96].
Hepatitis B reactivation is a major health problem. 
Patients undergoing immunosuppressive therapy are at 
risk of  developing hepatitis B reactivation. Acute liver 
failure requiring orthotopic liver transplantation has been 
reported in a patient under AZA and steroid treatment[97]. 
TNFα plays a role in hepatitis B virus replication, so 
anti-TNFα drugs could promote hepatitis B reactiva-
tion[98]. Infliximab, together with AZA or steroids, have 
been implicated in hepatitis B reactivation in seven cases 
from several series[94,99-102]. No cases have been reported 
in patients receiving adalimumab or certolizumab pegol. 
Nevertheless, hepatitis B reactivation seems to be a class-
effect, so more cases should be expected with the con-
tinuing use of  these new drugs. In patients with HBsAg 
loss reactivation is infrequent, but one case treated with 
infliximab has been reported[103]. A collaborative multi-
center and retrospective Spanish study (REPENTINA) 
showed a reactivation rate of  36% (9/25) in patients with 
positive HBsAg; six out of  nine developed liver failure, 
three underwent liver transplantation, and one died. No 
HBsAg-negative patients developed hepatitis B virus 
reactivation. In this study, the key factor for reactivation 
was the combination of  two or more immunosuppressive 
drugs, independently of  agent type. The absence of  reac-
tivation was associated with the use of  only one drug for 
a short period of  time[104]. 
Clinical practice guidelines from AEEH, EASL, and 
ECCO revised this topic and recommended prophylaxis 
of  hepatitis B reactivation in patients with IBD receiving 
immunosuppressive agents[104-106]. HBsAg, anti-HBc, and 
anti-HBs should be tested before immunosuppressive 
Table 1  Phases of chronic hepatitis B infection
Phase Characteristics HBVDNA ALT Liver histology
Immune tolerant HBeAg positive > 2000000 UI/mL Normal Normal or mild inflammation
Immune active HBeAg positive   > 200000 UI/mL Elevated Chronic hepatitis
Active cirrhosis
Inactive carrier HBeAg negative       < 2000 UI/mL Normal Normal or mild inflammation
Anti-HBe positive Mild fibrosis
Inactive cirrhosis
HBeAg negative chronic hepatitis HBeAg negative     > 20000 UI/mL Elevated Chronic hepatitis
Anti-HBe positive (fluctuating) Active cirrhosis
Remission HBsAg negative Indetectable in serum and detectable in liver Normal Normal
Anti-HBc positive Mild fibrosis
Inactive cirrhosis
HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen. 
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therapy with two goals: avoid possible fatal complications 
and use antiviral drugs to control hepatitis B virus rep-
lication: (1) HBV serologically-negative patients should 
receive vaccination. Vaccination rates in IBD are variable. 
In Spain, only 56% of  young people showed anti-HBs 
antibodies[95]. Vaccine response was around 46% using 
double doses in patients with IBD receiving anti-TNF 
drugs. However, AZA seems not to influence vaccine 
response. In non-responders a new complete vaccination 
course should be recommended. Hepatitis B screening 
is highly recommended immediately after the diagnosis 
of  IBD, and vaccination is indicated in serologically-
negative patients[107]; (2) Patients showing HBsAg positive 
and HBVDNA > 2000 IU/mL should be treated with 
tenofovir or entecavir as chronic hepatitis B patients; (3) 
Patients showing HBsAg positive and HBVDNA < 2000 
IU/mL or undetectable levels, and patients with HBsAg 
negative and HBVDNA positive should be treated with 
tenofovir or entecavir for 6 to 12 mo after the end of  
immunosuppressive therapy. ALT levels and HBVDNA 
titre should be monitored every three months during 
treatment; and (4) Patients showing HBsAg negative and 
anti-HBc positive with or without anti-HBs should be 
closely monitored every 1 to 3 mo, measuring ALT and 
HBVDNA until 6 to 12 mo after the end of  therapy. For 
patients with an increase in viral load, entecavir or teno-
fovir therapy should be immediately started. 
Hepatitis C and IBD
The prevalence of  hepatitis C infection was increased in 
IBD patients younger than 50-year-old in comparison 
with the general population in studies of  the last decade 
of  the twentieth century[94]. However, recent studies have 
demonstrated a similar prevalence to the general popula-
tion both in Spain (2.3% in CD and 1.3% in UC) and 
France (0.79% in CD and 1.59% in UC)[96,97].
The impact of  immunosuppressive therapy for IBD 
on hepatitis C remains controversial. Steroids could pro-
mote viral replication, as demonstrated after liver trans-
plantation. However, steroids have been used to treat 
hepatitis C without success or adverse events. ALT flares 
have been reported after stopping steroid therapy in pa-
tients with IBD[108]. Steroid therapy should be avoided in 
patients with hepatitis C, and patients should be closely 
monitored after any withdrawal or tapering process. Im-
munosuppressive drugs like AZA, MTX, cyclosporine, 
and mycophenolate mofetil have been largely used in 
the liver transplantation setting, showing a slight antivi-
ral activity against hepatitis C[109-111]. MTX did not affect 
hepatitis C disease in patients with arthritis[112]. Therefore, 
immunosuppressive therapy with these drugs seems to be 
safe. Indeed, in a Spanish study, 16% (8/51) of  patients 
with chronic hepatitis C and IBD receiving immunosup-
pressive therapy developed non-severe liver dysfunction, 
seven related to steroids, and one case with AZA[104]. 
TNFα plays a major role in the pathogenesis of  
chronic hepatitis C and associated metabolic abnor-
malities. TNFα is crucial in hepatitis C-induced insulin 
resistance, but could also modulate interferon response. 
Increased TNFα levels have been associated with im-
paired sustained virological response (SVR)[113]. Thus, 
TNFα inhibition could be more beneficial than harmful 
in the management of  chronic hepatitis C. Etanercept 
improved SVR in patients with chronic hepatitis C re-
ceiving peginterferon plus ribavirin[114]. Patients suffering 
from rheumatoid arthritis and hepatitis C treated with 
etanercept or infliximab did not show any changes in 
transaminases level or viral load[115]. Although etanercept 
is not effective on IBD, a class-effect should be expected, 
and the use of  anti-TNFα could be safe in hepatitis C as-
sociated with IBD.
CD is characterized by a Th1 response. Interferon 
seems to play an immunomodulatory activity-enhancing 
Th1 response, and can cause outbreak of  CD[116]. On 
the other hand, some authors have suggested that inter-
feron could be safely used in patients with IBD, due to 
a lack of  negative impact on the gut[117,118]. In a prospec-
tive study including 11 patients with IBD and hepatitis 
C, peginterferon plus ribavirin achieved SVR in a similar 
way to non-IBD patients. During treatment six patients 
developed gastrointestinal symptoms that required opti-
mization of  immunosuppressive agents without impact-
ing antiviral treatment[119]. Several case reports showed a 
beneficial effect of  interferon-alpha and beta on patients 
with UC[120,121]. A systematic review, including three pro-
spective studies, demonstrated no effect of  interferon-
alpha on UC[122], although new cases or exacerbation of  
UC have been seen in patients treated with interferon-
alpha[123,124]. Higher doses of  interferon used in hepatitis 
C, in comparison with lower doses in UC trials, could 
partially explain this discrepancy. Finally, 10 patients with 
CD and 10 with UC in remission or showing mild bowel 
activity underwent antiviral therapy for hepatitis C. No 
patient developed reactivation of  IBD during treatment 
or the 12 mo of  follow-up[125], confirming data from a 
recent review concluding that interferon does not impair 
IBD course[126]. 
In summary, hepatitis C antiviral treatment has no in-
fluence on IBD natural history, and immunosuppressive 
therapy for IBD does not promote reactivation of  hepa-
titis C. Currently, no therapeutic option for reactivation 
prophylaxis nor vaccination are available for hepatitis C, 
but in the near future interferon-free regimen combining 
protease, polymerase, and NS5A inhibitors could be use-
ful in the management of  hepatitis C in IBD. 
DRUG-INDUCED LIVER INJURY IN IBD
Approximately 30% of  patients with IBD show abnor-
malities in liver biochemical tests during the course of  the 
disease. Most of  the drugs used in IBD have potential 
hepatotoxicity[127] (Table 2).
Aminosalicylates: Sulfasalazine and mesalazine 
Sulfasalazine, an association between sulfapyridine and 
5-aminosalicylate (5-ASA), was the first aminosalicylate 
used in the treatment of  IBD. This drug has been re-
placed in the last two decades by mesalazine or 5-ASA, 
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due to its adverse effects. Mesalazine is indicated for the 
induction and maintenance of  the clinical remission in 
patients with UC with mild-moderate activity. The effi-
cacy of  this drug in CD remains controversial.
The anti-inflammatory effect of  aminosalicylates is 
unclear. Synthesis inhibition of  prostaglandins and leu-
kotrienes (which show antioxidant and immunomodula-
tory activity) are well known. Aminosalicylates are safe 
drugs, and rarely lead to severe adverse effects such 
as bone marrow aplasia, pancreatitis, nephropathy, or 
hepatotoxicity. Altered liver function tests (cytolysis or 
cholestasis) may be detected during treatment with them. 
These abnormalities usually have no clinical relevance, 
although hepatotoxicity induced by acute hypersensitiv-
ity and acute liver failure has been described. In clinical 
trials, abnormalities in liver biochemical tests have been 
observed in 2% of  UC patients treated with mesala-
zine[128]. The United Kingdom’s Committee on Safety of  
Medicines observed that, between 1991 and 1998, the 
incidence of  toxic hepatitis was 3.2 and 6 cases per mil-
lion of  prescriptions for mesalazine and sulfasalazine, 
respectively, and the presence of  rheumatoid arthritis was 
a stronger risk factor than IBD[129]. Therefore, given the 
low risk of  hepatotoxicity, a close monitoring of  liver 
biochemical tests is not necessary in patients treated with 
aminosalicylates.
Methotrexate
Methotrexate (MTX) has both anti-proliferative and im-
munosuppressive activities, impairing DNA synthesis (via 
inhibition of  dihydrofolate reductase) as well as decreas-
ing the production of  proinflammatory cytokines and 
inducing lymphocyte apoptosis, respectively. The main 
indication in IBD is maintenance of  clinical remission 
in steroid-dependent CD patients, after adverse effects 
or lack of  efficacy of  thiopurines. MTX efficacy in UC 
is controversial. On the other hand, MTX is contraindi-
cated in pregnancy. Regarding adverse effects, myelosup-
pression and hepatotoxicity are dose-dependent. These 
effects were documented in up to 25% of  patients with 
rheumatoid psoriatic arthritis, highlighting the association 
with obesity, alcoholism, diabetes, previous abnormalities 
in biochemical liver tests and, especially, an accumulated 
dose higher than 15 g, as risk factors. Currently, liver 
fibrosis and cirrhosis are less frequent, probably due to 
close monitoring of  liver parameters, proper selection 
of  patients, and simultaneous treatment with folic acid, 
which decreases MTX-related adverse effects. Sabeni et 
al[130], in Italy, detected hepatotoxicity in 14.3% of  pa-
tients with IBD treated with MTX during a mean follow-
up of  26 mo. Te et al[131], in the United States, carried 
out a study in 20 IBD-patients treated with MTX with 
a mean follow-up of  131 mo and accumulated doses 
of  2.6 g. Liver fibrosis in biopsies was detected in one 
patient; the rest of  the patients showed mild histological 
changes only. No association between abnormalities in 
liver biochemical tests and liver histology was found[131]. 
Regular liver laboratory studies are recommended in 
patients treated with MTX[132]. Nowadays, liver biopsy is 
not recommended routinely during MTX treatment[133]. 
However, it should be performed in cases of  persistent 
alteration of  transaminases (especially if  they do not de-
crease after reducing the drug dose) and in patients with 
high accumulated doses, together with other risk factors. 
On the other hand, transient elastography (Fibroscan®) is 
emerging as diagnostic method of  liver fibrosis in these 
patients. Treatment needs to be discontinued in cases of  
liver fibrosis or cirrhosis[134].
Anti-TNFα: Infliximab and adalimumab
Infliximab and adalimumab are monoclonal antibodies 
against TNFα, indicated in several rheumatologic, derma-
tologic, and gastrointestinal diseases. The main indication 
is the induction and maintenance of  clinical remission in 
steroid-resistant or steroid-dependent CD and UC pa-
tients without response to immunosuppressive therapy. 
Early on, they are recommended in CD associated with 
risk factors or in the presence of  severe perianal disease. 
Biological agents inhibit TNFα, preventing the release of  
proinflammatory cytokines, leukocyte migration, expres-
sion of  endothelial molecules, fibroblast proliferation, 
and prostaglandin synthesis.
The main adverse effects of  these drugs are op-
portunistic infections, hepatitis B virus reactivation, 
lymphoproliferative diseases, neurological diseases, and 
autoimmune diseases, such as lupus-like syndromes. 
Severe hepatotoxicity is a very rare condition in biologi-
cal therapy, being most frequent in patients treated with 
infliximab. It is difficult to determine cause-effect asso-
ciations between liver damage and these drugs in some 
cases due to confounding factors, like the presence of  
other drugs and other concomitant diseases. The drug 
label of  infliximab (Remicade®) showed that, in clinical 
trials, ALT raised more than three times in 4.9% of  pa-
tients with CD and in 2.5% of  patients with UC, without 
clinical relevance. In contrast, serum ALT levels were less 
altered in the placebo group. On the other hand, the drug 
label of  adalimumab (Humira®) indicates that serum ALT 
levels were similar in patients with IBD and a placebo. 
Table 2  Drug induced hepatobiliary manifestations in 
inflammatory bowel disease
Manifestation Drug
Drug induced hepatitis Azathioprine
6-mercaptopurine
Methotrexate
Cyclosporine
Infliximab
Reactivation of hepatitis B Anti-TNF therapy
Corticosteroids
Drug induced pancreatitis Azathioprine
6-mercaptopurine
Methotrexate
Hepatosplenic T-cell lymphoma Combination of anti-TNF and 
immunosuppressive therapy
TNF: Tumor necrosis factor.
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According to infliximab indications, jaundice has been an 
uncommon finding, as well as infectious hepatitis, with 
liver failure being a very rare condition[135]. The Food and 
Drug Administration considers infliximab a hepatotoxic 
drug[136]. Recently, hepatotoxicity by these drugs has been 
evaluated in the United States (2003-2011), where only 
34 cases were found, confirming the peculiarity of  this 
adverse effect. Most cases (76%) were related to inflix-
imab, showing a hepatocellular or cholestatic pattern with 
autoimmune characteristics, and improving after discon-
tinuation of  the drug[137]. Cross hepatotoxicity has not 
been documented in anti-TNF agents. In fact, in cases of  
infliximab-induced hepatotoxicity, adalimumab has been 
shown to be safe[138].
Thiopurines (azathioprine and 6-mercaptopurine) 
AZA and its metabolite, 6-mercaptopurine (MP), are the 
immunosuppressive agents most commonly used in IBD. 
They are purine analogues, which interfere in nucleic acid 
synthesis and inhibit the proliferation of  B and T lym-
phocytes, although the most relevant action is the apop-
totic activation of  T lymphocytes. The main indication of  
these drugs in CD and UC is the maintenance of  clinical 
remission, preventing the use of  steroids.
The active metabolites of  AZA and MP are the 
6-thioguanine nucleotides. In the liver, AZA is modi-
fied to MP, which is metabolized by xanthine oxidase 
and thiopurine methyltransferase (TPMT) in 6-thiouric 
acid and 6-methylmercaptopurine, resulting ultimately in 
6-thioguanine nucleotides by hypoxanthine phosphoribo-
syltransferase. The decreased activity of  TPMT facilitates 
the increasing in 6-thioguanine nucleotide levels, which 
are related to adverse effects. In fact, the efficacy of  AZA 
and MP is limited owing to their adverse effects, which 
are responsible for treatment discontinuations in up to 
15% of  patients. Adverse effects are classified as dose-
independent, dose-dependent, or idiosyncratic (which 
appears during the first two weeks of  treatment). Regard-
ing dose-independent adverse effects, the most common 
are allergic reactions (fever, exanthema, myalgias, and ar-
thralgias) and acute pancreatitis. Among dose-dependent 
adverse effects, gastrointestinal intolerance and myelotox-
icity are present in 2%-5% of  patients. In retrospective 
studies, hepatotoxicity affected 3% of  patients with an 
annual incidence of  1.4%, while these results are higher 
in prospective studies (10%)[139]. AZA and MP are able 
to damage the vascular endothelium, especially sinusoids 
and terminal veins, promoting veno-occlusive disease, 
regenerative nodular hyperplasia, and liver peliosis. These 
complications could be detected between 3 mo and 3 
years after the beginning of  treatment, and generate 
portal hypertension[140,141]. In general, mechanisms for 
AZA and MP hepatotoxicity remain unclear. It is thought 
that the main reason is the intracellular accumulation of  
6-thioguanine nucleotides due to the decreased activity of  
TPMT.
It is recommended to determine levels of  TPMT 
before the beginning of  treatment with AZA or MP and 
routinely perform liver biochemical tests, especially dur-
ing the first months of  treatment, to detect myelotoxicity 
and/or hepatotoxicity. Mild abnormalities in liver pa-
rameters, without clinical relevance, allow the continua-
tion of  treatment at a lower dose. However, jaundice or 
persistent alterations in spite of  reduced dose require an 
immediate stop to treatment[142].
CONCLUSION
Hepatobiliary disorders are common extraintestinal mani-
festations of  IBD, and PSC represents the most prevalent 
disease among them. Abnormal liver biochemical tests 
are present in up to 30 percent of  patients with IBD and 
emerge as a diagnostic challenge. Drug-induced hepa-
totoxicity should always be rule out, as most IBD treat-
ments have been associated with liver toxicity, although 
the incidence of  serious complications is low. Hepatitis 
B screening and vaccination is recommended in patients 
with IBD. Reactivation prophylaxis with entecavir or 
tenofovir is mandatory in patients under immunosup-
pressive therapy showing HBsAg positive, independently 
from viral load. HBsAg negative and anti-HBc positive 
patients, with or without anti-HBs, should be closely 
monitored, and treated if  the viral load increase. Diag-
nosis complexity often requires a joint gastroenterologist 
and hepatologist approach.
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